Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 1

Conditions

Recurrence 1Neoplasm Metastasis 1Glioblastoma 1Delirium 1

Interventions

pembrolizumab 1262Specimen Handling 924Magnetic Resonance Spectroscopy 829Carboplatin 821Cyclophosphamide 799Cisplatin 722Nivolumab 667Paclitaxel 627Radiotherapy 608Gemcitabine 570Biopsy 557Bevacizumab 478Dexamethasone 437fludarabine 407Docetaxel 377venetoclax 367Oxaliplatin 364Capecitabine 355Fluorouracil 355atezolizumab 350durvalumab 332Rituximab 329Drug Therapy 325Doxorubicin 316Radiosurgery 314Standard of Care 309Blood Specimen Collection 308Pemetrexed 304Ipilimumab 298Radiation 285

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Chlorpromazine × 1 year × Clear all
NCT03021486 2026-03-18

Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer

M.D. Anderson Cancer Center

Phase 2/3 Active not recruiting
70 enrolled 20 charts

Delirium, Neoplasm Metastasis, Recurrence

NCT05190315 2025-09-02

Chlorpromazine and Standard of Care in Glioblastoma

University of Iowa

Phase 1 Completed
10 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡